Autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, diabetes and lupus, etc., affect approximately 50 million Americans. The immune responses of self-reactive T lymphocytes play critical roles in autoimmune diseases. Therefore, identification of novel molecules that regulate T cell immune functions are important for a better understanding of the mechanisms underlying the disease development and for seeking novel therapies. During the current finding period, we have discovered that the type III histone deacetylase Sirt1 as a critical suppressor to T cell immunity and macrophage activation by suppressing the transcription factors AP-1, indicating Sirt1 as a potential therapeutic target for autoimmune and inflammatory diseases. In fact, we further demonstrated that the Sirt1 activator resveratrol prevents/treats type 1 diabetes in mice. Our preliminary study of the current competitive renewal application demonstrates that the deacetylase Sirt1 and the acetyltransferase GCN5 oppositely regulate T cell activation. Genetic deletion of GCN5 gene inhibits T cell immune responses in mice, identifying GCN5 as a critical positive regulator for T cell immunity. Interestingly, treatment of mice with GCN5 specific inhibitor attenuated autoimmune disease development. Therefore, based on the above preliminary findings, we propose that the histone deacetylase Sirt1 is a negative regulator and the acetyltransferase GCN5 is a positive regulator for T cell immunity, and that the Sirt1 activator and GCN5 inhibitor have great therapeutic potentials in treatment of autoimmune diseases. This project is to address this hypothesis using the state-of-art approaches of both immunological and molecular studies. Results from this proposed study discover novel molecular mechanisms behind Sirt1 and GCN5 in T cell activation and autoimmunity, providing rationales for the uses of Sirt1 deacetylase activators and GCN5 acetyltransferase inhibitors in treating/preventing autoimmune diseases.
This study identifies the histone deacetylase Sirt1 as a negative regulator and the acetyltransferase GCN5 as a positive regulator for T cell immune response. Therefore, Sirt1 activators and GCN5 inhibitors have great therapeutic potentials in the treatment of autoimmune diseases.
|Kong, Sinyi; Thiruppathi, Muthusamy; Qiu, Quan et al. (2014) DBC1 is a suppressor of B cell activation by negatively regulating alternative NF-?B transcriptional activity. J Immunol 193:5515-24|
|Yang, Heeyoung; Qiu, Quan; Gao, Beixue et al. (2014) Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation. J Exp Med 211:2467-79|
|Kong, Sinyi; Yeung, Pricilla; Fang, Deyu (2013) The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis. J Genet Genomics 40:347-54|
|Chen, Weimin; Wang, Huihui; Tao, Shasha et al. (2013) Tumor protein translationally controlled 1 is a p53 target gene that promotes cell survival. Cell Cycle 12:2321-8|
|Zou, Ting; Yang, Yi; Xia, Fei et al. (2013) Resveratrol Inhibits CD4+ T cell activation by enhancing the expression and activity of Sirt1. PLoS One 8:e75139|
|Lei, Fengyang; Song, Jianyong; Haque, Rizwanul et al. (2013) Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity. PLoS One 8:e70635|
|Kemp, Kyeorda L; Lin, Zhenghong; Zhao, Fang et al. (2013) The serine-threonine kinase inositol-requiring enzyme 1* (IRE1*) promotes IL-4 production in T helper cells. J Biol Chem 288:33272-82|
|Qiu, Quan; Zheng, Ze; Chang, Lin et al. (2013) Toll-like receptor-mediated IRE1* activation as a therapeutic target for inflammatory arthritis. EMBO J 32:2477-90|
|Lin, Zhenghong; Fang, Deyu (2013) The Roles of SIRT1 in Cancer. Genes Cancer 4:97-104|
|Chen, Weiming; Wang, Huihui; Tao, Shasha et al. (2013) Tumor protein translationally controlled 1 is a p53 target gene that promotes cell survival. Cell Cycle 12:|
Showing the most recent 10 out of 18 publications